Changing Genotypic Distribution, Antimicrobial Susceptibilities, and Risk Factors of Urinary Tract Infection Caused by Carbapenemase-Producing Pseudomonas aeruginosa

키워드

참고문헌 (40)

1. Weiner-Lastinger LM, "Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017", Infect Control Hosp Epidemiol, 41, pp.1~18 (2020)
2. Lucena A, "Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes", J Hosp Infect, 87, pp.234~240 (2014)
3. Diene SM, "Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species", Clin Microbiol Infect, 20, pp.831~838 (2014)
4. Tenover FC, "Carbapenemase-producing Pseudomonas aeruginosa-an emerging challenge", Emerg Microbes Infect, 11, pp.811~814 (2022)
5. Almarzoky Abuhussain SS, "In vitro potency of antipseudomonal beta-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals", J Thorac Dis, 11, pp.1896~1902 (2019)
6. Woodworth KR, "Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms - United States, 2006-2017", MMWR Morb Mortal Wkly Rep, 67, pp.396~401 (2018)
7. Yong D, "Increase in the prevalence of carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-typhoidal Salmonella species in Korea : a KONSAR study conducted in 2011", Infect Chemother, 46, pp.84~93 (2014)
8. Bae MH, "Changing epidemiology of pathogenic bacteria over the past 20 years in Korea", J Korean Med Sci, 38, pp.e73~ (2023)
9. Wang MG, "Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa", Antibiotics(Basel), 10, pp.548~ (2021)
10. Livermore DM, "Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa : our worst nightmare?", Clin Infect Dis, 34, pp.634~640 (2002)
11. Yoon EJ, "Mobile carbapenemase genes in Pseudomonas aeruginosa", Front Microbiol, 12, pp.614058~ (2021)
12. Grupper M, "Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds", Antimicrob Agents Chemother, 61, pp.e00875-17~ (2017)
13. Zavascki AP, "The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections", J Antimicrob Chemother, 58, pp.387~392 (2006)
14. Corvec S, "Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme", J Hosp Infect, 68, pp.73~82 (2008)
15. Kouda S, "Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the blaIMP-1 gene cassette in Hiroshima", J Antimicrob Chemother, 64, pp.46~51 (2009)
16. CLSI, "Performance standards for antimicrobial susceptibility testing. 31st informational supplement" (2021), Clinical and Laboratory Standards Institute
17. Jeong S, "Genotypic distribution and antimicrobial susceptibilities of carbapenemase-producing Enterobacteriaceae isolated from rectal and clinical samples in Korean university hospitals between 2016 and 2019", Ann Lab Med, 42, pp.36~46 (2022)
18. Garner JS, "CDC definitions for nosocomial infections, 1988", Am J Infect Control, 16, pp.128~140 (1988)
19. Bongiovanni M, "Impact of the COVID-19pandemic on multidrug-resistant hospital-acquired bacterial infections", J Hosp Infect, 123, pp.191~192 (2022)
20. Jeon K, "Impact of COVID-19 on antimicrobial consumption and spread of multidrug-resistance in bacterial infections", Antibiotics(Basel), 11, pp.535~ (2022)
21. Ruiz-Garbajosa P, "COVID-19 : impact on prescribing and antimicrobial resistance", Rev Esp Quimioter, 34(S1), pp.63~68 (2021)
22. O’Toole RF, "The interface between COVID-19 and bacterial healthcareassociated infections", Clin Microbiol Infect, 27, pp.1772~1776 (2021)
23. Perez LRR, "Emergence of NDM-producing Pseudomonas aeruginosa among hospitalized patients and impact on antimicrobial therapy during the coronavirus disease 2019(COVID-19)pandemic", Infect Control Hosp Epidemiol, 43, pp.1279~1280 (2022)
24. Lee K, "bla(VIM-2)cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital", Antimicrob Agents Chemother, 46, pp.1053~1058 (2002)
25. Seok Y, "Dissemination of IMP-6metallo-beta-lactamase-producing Pseudomonas aeruginosa sequence type 235 in Korea", J Antimicrob Chemother, 66, pp.2791~2796 (2011)
26. Park Y, "Epidemiology, molecular characteristics, and virulence factors of carbapenem-resistant Pseudomonas aeruginosa isolated from patients with urinary tract infections", Infect Drug Resist, 15, pp.141~151 (2022)
27. Hong JS, "Molecular characterization of the first emerged NDM-1-producing Pseudomonas aeruginosa isolates in South Korea", Microb Drug Resist, 27, pp.1063~1070 (2021)
28. Khan A, "Simultaneous infection with Enterobacteriaceae and Pseudomonas aeruginosa harboring multiple carbapenemases in a returning traveler colonized with Candida auris", Antimicrob Agents Chemother, 64, pp.e01466-19~ (2020)
29. Perez F, "Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae : can we apply"precision medicine"to antimicrobial chemotherapy?", Expert Opin Pharmacother, 17, pp.761~781 (2016)
30. Marshall S, "Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?", Antimicrob Agents Chemother, 61, pp.e02243-16~ (2017)
31. Walsh TR, "Metallo-beta-lactamases : the quiet before the storm?", Clin Microbiol Rev, 18, pp.306~325 (2005)
32. Esposito F, "Genomic analysis of carbapenem-resistant Pseudomonas aeruginosa isolated from urban rivers confirms spread of clone sequence Type 277 carrying broad resistome and virulome beyond the hospital", Front Microbiol, 12, pp.701921~ (2021)
33. Mauri C, "The revival of aztreonam in combination with avibactam against metallo-β-lactamaseproducing gram-negatives : a systematic review of in vitro studies and clinical cases", Antibiotics(Basel), 10, pp.1012~ (2021)
34. Barron MA, "Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites", Springerplus, 5, pp.755~ (2016)
35. Tsao LH, "Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa", J Microbiol Immunol Infect, 51, pp.359~366 (2018)
36. Lipsitch M, "Antimicrobial use and antimicrobial resistance : a population perspective", Emerg Infect Dis, 8, pp.347~354 (2002)
37. Hirakata Y, "Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa", Clin Infect Dis, 37, pp.26~32 (2003)
38. Shi Q, "A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections", Antimicrob Resist Infect Control, 8, pp.68~ (2019)
39. Zhang Y, "Risk factors for mortality of inpatients with Pseudomonas aeruginosa bacteremia in China : impact of resistance profile in the mortality", Infect Drug Resist, 13, pp.4115~4123 (2020)
40. George EL, "Does a high WBC count signal infection?", Nursing, 35, pp.20~21 (2005)

관련 논문AI추천